Goldman Sachs’s Endologix Inc ELGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-76,798
Closed -$556K 5557
2019
Q2
$556K Buy
76,798
+56,171
+272% +$383K ﹤0.01% 4342
2019
Q1
$136K Sell
20,627
-3,807
-16% -$25.1K ﹤0.01% 4879
2018
Q4
$175K Sell
24,434
-277
-1% -$3.08K ﹤0.01% 4866
2018
Q3
$472K Buy
24,711
+7,184
+41% +$256K ﹤0.01% 4453
2018
Q2
$992K Sell
17,527
-10,114
-37% -$513K ﹤0.01% 4082
2018
Q1
$1.17M Buy
27,641
+3,390
+14% +$146K ﹤0.01% 3950
2017
Q4
$1.3M Sell
24,251
-28,833
-54% -$1.52M ﹤0.01% 4135
2017
Q3
$2.37M Buy
53,084
+3,725
+8% +$170K ﹤0.01% 3826
2017
Q2
$2.4M Buy
49,359
+20,829
+73% +$1.23M ﹤0.01% 3691
2017
Q1
$2.07M Buy
28,530
+21,218
+290% +$1.4M ﹤0.01% 3717
2016
Q4
$418K Sell
7,312
-159,413
-96% -$14.6M ﹤0.01% 5212
2016
Q3
$21.3M Sell
166,725
-106,338
-39% -$13.6M 0.01% 1840
2016
Q2
$34M Sell
273,063
-127,244
-32% -$14.6M 0.01% 1380
2016
Q1
$33.5M Sell
400,307
-27,755
-6% -$2.29M 0.01% 1352
2015
Q4
$42.4M Sell
428,062
-19,455
-4% -$2.09M 0.01% 1234
2015
Q3
$54.9M Buy
447,517
+72,099
+19% +$9.79M 0.02% 982
2015
Q2
$57.6M Buy
375,418
+3,815
+1% +$630K 0.02% 1014
2015
Q1
$63.4M Buy
371,603
+169,762
+84% +$25.7M 0.02% 917
2014
Q4
$30.9M Buy
201,841
+11,634
+6% +$1.45M 0.01% 1499
2014
Q3
$20.2M Sell
190,207
-53,713
-22% -$7.48M 0.01% 1787
2014
Q2
$37.1M Buy
243,920
+15,741
+7% +$2.09M 0.01% 1317
2014
Q1
$29.4M Buy
228,179
+224,943
+6,951% +$35M 0.01% 1454
2013
Q4
$564K Buy
3,236
+802
+33% +$138K ﹤0.01% 5215
2013
Q3
$393K Sell
2,434
-2,924
-55% -$460K ﹤0.01% 5341
2013
Q2
$712K Buy
+5,358
New +$756K ﹤0.01% 4662

Other funds holding ELGX

Goldman Sachs's ELGX Position: Q3 2019 in Review

Goldman Sachs sold out of Endologix Inc (ELGX) in Q3 2019, closing a stake of 76,798 shares — an estimated $556K sold.

Goldman Sachs first reported a position in ELGX in Q2 2013 and held it in 25 quarters. The position peaked at $63.4M in Q1 2015. 63 funds tracked by Wall St. Rank hold ELGX as of Q3 2019.

  • Goldman Sachs reported no remaining Endologix Inc position as of Q3 2019 after selling out during the quarter.
  • Goldman Sachs sold 76,798 Endologix Inc shares in Q3 2019, an estimated $556K.
  • Goldman Sachs first reported a position in Endologix Inc in Q2 2013 and held it in 25 quarters.
  • Goldman Sachs's Endologix Inc position peaked at $63.4M in Q1 2015.
  • 63 funds tracked by Wall St. Rank held Endologix Inc as of Q3 2019.

Based on Goldman Sachs's 13F filing for Q3 2019, filed 14 Nov 2019.